CSPC Pharmaceutical Group Ltd. announced that their drug CPO301 has been granted its third Fast Track designation by the U.S. Food and Drug Administration (FDA). This designation is for the treatment of adult patients with advanced or metastatic non-squamous non-small cell lung cancer (Nsq-NSCLC) without EGFR mutations, who have experienced disease progression following platinum-based chemotherapy and anti-PD-$(L)$1 antibody treatment. This marks the third Fast Track designation for CPO301, following previous designations for other NSCLC treatment contexts. The Fast Track status will aid in expediting the development and registration processes for CPO301 in the U.S. and globally. No other organizations were mentioned in obtaining this grant.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。